Allspring Global Investments Holdings LLC Grows Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Allspring Global Investments Holdings LLC increased its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 40.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,760,781 shares of the medical research company's stock after buying an additional 509,163 shares during the quarter. Allspring Global Investments Holdings LLC owned 3.42% of Charles River Laboratories International worth $346,821,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. grew its holdings in shares of Charles River Laboratories International by 1.1% during the first quarter. Vanguard Group Inc. now owns 6,046,467 shares of the medical research company's stock worth $1,638,290,000 after purchasing an additional 66,161 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC increased its position in Charles River Laboratories International by 1.7% in the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,908,989 shares of the medical research company's stock valued at $394,359,000 after acquiring an additional 31,359 shares in the last quarter. Clearbridge Investments LLC raised its stake in shares of Charles River Laboratories International by 3.1% in the first quarter. Clearbridge Investments LLC now owns 1,513,138 shares of the medical research company's stock worth $409,985,000 after acquiring an additional 45,079 shares during the last quarter. Meritage Group LP lifted its position in shares of Charles River Laboratories International by 2.3% during the first quarter. Meritage Group LP now owns 1,182,268 shares of the medical research company's stock worth $320,336,000 after purchasing an additional 26,892 shares in the last quarter. Finally, Earnest Partners LLC raised its position in Charles River Laboratories International by 12.4% in the 2nd quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company's stock worth $207,507,000 after purchasing an additional 110,725 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on CRL shares. StockNews.com raised Charles River Laboratories International from a "hold" rating to a "buy" rating in a research note on Wednesday. JPMorgan Chase & Co. lowered Charles River Laboratories International from an "overweight" rating to a "neutral" rating and lowered their price objective for the stock from $270.00 to $205.00 in a research report on Thursday, August 8th. The Goldman Sachs Group cut their target price on shares of Charles River Laboratories International from $290.00 to $250.00 and set a "buy" rating on the stock in a research report on Thursday, August 8th. Baird R W downgraded shares of Charles River Laboratories International from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 8th. Finally, TD Cowen lowered their target price on shares of Charles River Laboratories International from $228.00 to $203.00 and set a "hold" rating for the company in a report on Monday, August 12th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International presently has an average rating of "Hold" and an average target price of $212.23.

Charles River Laboratories International Stock Down 0.0 %

Shares of NYSE:CRL traded down $0.01 during mid-day trading on Friday, reaching $197.77. 707,810 shares of the stock were exchanged, compared to its average volume of 596,940. The stock's 50 day simple moving average is $197.20 and its 200-day simple moving average is $213.73. Charles River Laboratories International, Inc. has a one year low of $161.65 and a one year high of $275.00. The company has a market cap of $10.19 billion, a P/E ratio of 23.27, a P/E/G ratio of 5.11 and a beta of 1.36. The company has a quick ratio of 1.21, a current ratio of 1.58 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The medical research company reported $2.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.39 by $0.41. The business had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.03 billion. Charles River Laboratories International had a net margin of 10.83% and a return on equity of 14.96%. As a group, equities research analysts predict that Charles River Laboratories International, Inc. will post 10.01 EPS for the current year.

Charles River Laboratories International declared that its Board of Directors has initiated a share repurchase program on Wednesday, August 7th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase up to 9.6% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's leadership believes its shares are undervalued.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).